IGFBP-2 and aging: a 20-year longitudinal study on IGFBP-2, IGF-I, BMI, insulin sensitivity and mortality in an aging population

in European Journal of Endocrinology
Correspondence should be addressed to A W van den Beld; Email: a.vandenbeld@erasmusmc.nl
Restricted access

48-hour access to this article

USD $30.00


Insulin-like growth factor-binding protein-2 (IGFBP-2) concentrations are low in subjects with metabolic syndrome and type 2 diabetes. Intriguingly, recent studies have demonstrated an association between high IGFBP-2 concentrations and increased mortality not only in populations with certain types of cancer, but also in relatively healthy populations. We evaluated the role of IGFBP-2 in relation to BMI and mortality.

Design and Participants

BMI, insulin sensitivity, insulin-like growth factor 1 (IGF-I) and IGFBP-2 were assessed repeatedly in 539 participants of the Baltimore Longitudinal Study of Aging around the ages of 55, 65 and 75 years.


IGFBP-2 concentrations positively correlated with insulin sensitivity and inversely with BMI, both at baseline and follow-up. Independent of IGF-I, sex, BMI and insulin sensitivity, circulating IGFBP-2 levels positively correlated with age (P < 0.001). Changes over time in BMI were associated with an inverse correlation in IGFBP-2 concentrations. Furthermore, we found indications of a relationship between low baseline IGFBP-2 levels and mortality. Remarkably, after adjustment for insulin sensitivity, the opposite association was found, as a unit increase of log(IGFBP2) was associated with an increase in the log hazard by 1.43 (95% CI: 0.3–2.6). This accounted for both baseline (P = 0.02) as well as serial (P < 0.001) measurements of IGFBP2. Finally, in this longitudinal study, we found that IGF-I concentrations increased with age (0.82 ± 0.2 (µg/L)/year, P < 0.001).


This is the first study investigating the relationship between IGFBP-2 levels and age in a longitudinal setting. Serum IGFBP-2 levels increase with age after the age of 50 years and evolve in parallel with insulin sensitivity. IGFBP-2 may therefore be a potential marker for insulin sensitivity. We further show that IGFBP-2 levels can predict mortality in this aging population. However, its predictive value for mortality can only be interpreted in relation to insulin sensitivity. After adjustment for insulin sensitivity, high IGFBP-2 levels are predictive of increased mortality.


Official journal of

European Society of Endocrinology




ToogoodAAShaletSM. Ageing and growth hormone status. Bailliere’s Clinical Endocrinology and Metabolism 1998 12 281296. (https://doi.org/10.1016/S0950-351X(98)80023-2)


YauSWAzarWJSabinMAWertherGARussoVC. IGFBP-2 - taking the lead in growth, metabolism and cancer. Journal of Cell Communication and Signaling 2015 9 125142. (https://doi.org/10.1007/s12079-015-0261-2)


BorstSEMillardWJLowenthalDT. Growth hormone, exercise, and aging: the future of therapy for the frail elderly. Journal of the American Geriatrics Society 1994 42 528535. (https://doi.org/10.1111/j.1532-5415.1994.tb04976.x)


BartkeASunLYLongoV. Somatotropic signaling: trade-offs between growth, reproductive development, and longevity. Physiological Reviews 2013 93 571598. (https://doi.org/10.1152/physrev.00006.2012)


WheatcroftSBKearneyMTShahAMEzzatVAMiellJRModoMWilliamsSCCawthornWPMedina-GomezGVidal-PuigA et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007 56 285294. (https://doi.org/10.2337/db06-0436)


HedbackerKBirsoyKWysockiRWAsilmazEAhimaRSFarooqiISFriedmanJM. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metabolism 2010 11 1122. (https://doi.org/10.1016/j.cmet.2009.11.007)


FrystykJSkjaerbaekCVestboEFiskerSOrskovH. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes/Metabolism Research and Reviews 1999 15 314322. (https://doi.org/10.1002/(SICI)1520-7560(199909/10)15:5<314::AID-DMRR56>3.0.CO;2-E)


HealdAHKaushalKSiddalsKWRudenskiASAndersonSGGibsonJM. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Experimental and Clinical Endocrinology and Diabetes 2006 114 371376. (https://doi.org/10.1055/s-2006-924320)


van den BeldAWBlumWFBrugtsMPJanssenJAGrobbeeDELambertsSW. High IGFBP2 levels are not only associated with a better metabolic risk profile but also with increased mortality in elderly men. European Journal of Endocrinology 2012 167 111117. (https://doi.org/10.1530/EJE-12-0160)


FazeliPKLawsonEAPrabhakaranRMillerKKDonohoDAClemmonsDRHerzogDBMisraMKlibanskiA. Effects of recombinant human growth hormone in anorexia nervosa: a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2010 95 48894897. (https://doi.org/10.1210/jc.2010-0493)


PickardAMcCanceDJ. IGF-binding protein 2: Oncogene of Tumor Suppresor?. Frontiers in Endocrinology 2015 6 25. (https://doi.org/10.3389/fendo.2015.00025)


LiouJMShunCTLiangJTChiuHMChenMJChenCCWangHPWuMSLinJT. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. Journal of Clinical Endocrinology and Metabolism 2010 95 17171725. (https://doi.org/10.1210/jc.2009-2668)


Baron-HaySBoyleFFerrierAScottC. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clinical Cancer Research 2004 10 17961806. (https://doi.org/10.1158/1078-0432.CCR-0672-2)


Probst-HenschNMSteinerJHSchramlPVargaZZurrer-HardiUStorzMKorolDFehrMKFinkDPestalozziBC et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clinical Cancer Research 2010 16 10251032. (https://doi.org/10.1158/1078-0432.CCR-09-0957)


HuDPawlikowskaLKanayaAHsuehWCColbertLNewmanABSatterfieldSRosenCCummingsSRHarrisTB et al. Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: the Health, Aging, and Body Composition Study. Journal of the American Geriatrics Society 2009 57 12131218. (https://doi.org/10.1111/j.1532-5415.2009.02318.x)


ShockNWGreulichRCCostaPTJrAndresRLakattaEGArenbergDTobinJD. Normal Human Aging. Washington D.C.: U.S. Govt. Printing office (1984 edn.). the Baltimore longitudinal Study of aging 84–2450 Ed NIo Health.


LissnerLAndresRMullerDCShimokataH. Body weight variability in men: metabolic rate, health and longevity. International Journal of Obesity 1990 14 373383.


TheodorakisMJCarlsonOMullerDCEganJM. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care 2004 27 16921698. (https://doi.org/10.2337/diacare.27.7.1692)


MatsudaMDeFronzoRA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 14621470. (https://doi.org/10.2337/diacare.22.9.1462)


VerbekeGFieuwsSMolenberghsGDavidianM. The analysis of multivariate longitudinal data: a review. Statistical Methods in Medical Research 2017 26 112. (https://doi.org/10.1177/0962280214539862)


RizopoulosDTakkenbergJJ. Tools & techniques – statistics: dealing with time-varying covariates in survival analysis – joint models versus Cox models. EuroIntervention 2014 10 285288. (https://doi.org/10.4244/EIJV10I2A47)


BlumWFBreierBH. Radioimmunoassays for IGFs and IGFBPs. Growth Regulation 1994 4 (Supplement 1) 1119.


JonesJIDoerrMEClemmonsDR. Cell migration: interactions among integrins, IGFs and IGFBPs. Progress in Growth Factor Research 1995 6 319327. (https://doi.org/10.1016/0955-2235(95)00015-1)


LiZMiardSLaplanteMSonenbergNPicardF. Insulin stimulates IGFBP-2 expression in 3T3-L1 adipocytes through the PI3K/mTOR pathway. Molecular and Cellular Endocrinology 2012 358 6368. (https://doi.org/10.1016/j.mce.2012.02.022)


AsilmazECohenPMiyazakiMDobrzynPUekiKFayzikhodjaevaGSoukasAAKahnCRNtambiJMSocciND et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. Journal of Clinical Investigation 2004 113 414424. (https://doi.org/10.1172/JCI200419511)


YauSWHenryBARussoVCMcConellGKClarkeIJWertherGASabinMA. Leptin enhances insulin sensitivity by direct and sympathetic nervous system regulation of muscle IGFBP-2 expression: evidence from nonrodent models. Endocrinology 2014 155 21332143. (https://doi.org/10.1210/en.2013-2099)


YoungNJMetcalfeCGunnellDRowlandsMALaneJAGilbertRAveryKNDavisMNealDEHamdyFC et al. A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, And IGFBP-3 in men in the United Kingdom. Cancer Causes and Control 2012 23 907917. (https://doi.org/10.1007/s10552-012-9961-6)


Closa-MonasteroloRFerreNLuqueVZaragoza-JordanaMGroteVWeberMKoletzkoBSochaPGruszfeldDJanasR et al. Sex differences in the endocrine system in response to protein intake early in life. American Journal of Clinical Nutrition 2011 94 1920S1927S. (https://doi.org/10.3945/ajcn.110.001123)


BlumWFHornNKratzschJJorgensenJOJuulATealeDMohnikeKRankeMB. Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regulation 1993 3 100104.


MattssonASvenssonDSchuettBOsterzielKJRankeMB. Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults. Growth Hormone and IGF Research 2008 18 506516. (https://doi.org/10.1016/j.ghir.2008.04.005)


van den BeldAWBlumWFPolsHAGrobbeeDELambertsSW. Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. European Journal of Endocrinology 2003 148 627634. (https://doi.org/10.1530/eje.0.1480627)


XiGSolumMAWaiCMaileLARosenCJClemmonsDR. The heparin-binding domains of IGFBP-2 mediate its inhibitory effect on preadipocyte differentiation and fat development in male mice. Endocrinology 2013 154 41464157. (https://doi.org/10.1210/en.2013-1236)


YaoXSunSZhouXGuoWZhangL. IGF-binding protein 2 is a candidate target of therapeutic potential in cancer. Tumour Biology 2016 37 14511459. (https://doi.org/10.1007/s13277-015-4561-1)


CountsDRGwirtsmanHCarlssonLMLesemMCutlerGBJr. The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. Journal of Clinical Endocrinology and Metabolism 1992 75 762767.


Di SommaCBrunelliVSavanelliMCScaranoESavastanoSLombardiGColaoA. Somatopause: state of the art. Minerva Endocrinol 2011 36 243255.


SandersJLGuoWO’MearaESKaplanRCPollakMNBartzTMNewmanABFriedLPCappolaAR. Trajectories of IGF-I predict mortality in older adults: the cardiovascular Health Study. Journals of Gerontology: Series A Biological Sciences and Medical Sciences 2018 73 953959. (https://doi.org/10.1093/gerona/glx143)


BannDHollyJMPLashenHHardyRAdamsJKuhDOngKKBen-ShlomoY. Changes in insulin-like growth factor-I and -II associated with fat but not lean mass in early old age. Obesity 2015 23 692698. (https://doi.org/10.1002/oby.21002)


KaplanRCBuzkovaPCappolaARStricklerHDMcGinnAPMercerLDArnoldAMPollakMNNewmanAB. Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study. Journal of Clinical Endocrinology and Metabolism 2012 97 19701976. (https://doi.org/10.1210/jc.2011-2967)

Index Card


Google Scholar

Related Articles



All Time Past Year Past 30 Days
Abstract Views 292 292 270
Full Text Views 52 52 47
PDF Downloads 18 18 15